University of Toronto

Two MI inventors named to MIT’s 35 inventors under 35 list

August 24, 2012
Susanne Staer
Awards

Professors Joyce Poon and Hossein Rahnama, who each have inventions within MaRS Innovation’s portfolio of spin-off companies and licenseable technologies, have been named to the MIT Technology Review‘s prestigious 35 Inventors Under 35 list for 2012.

Poon, an assistant professor of electrical and computer engineering at the University of Toronto, was recognized for, according to MIT’s Technology Review, “creating new optical modulators with microscopic loop-the-loops through which light can shuttle data between servers and even from chip to chip within a single server.” She is working with MaRS Innovation to license her technology.

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can…

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).

Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt:…

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.

The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

University of Toronto: Snapshot of Toronto’s Entrepreneurship Scene

The University of Toronto’s news site has posted a brief snapshot of Toronto’s entrepreneurial scene, highlighting the university’s historical and current innovative strengths.

Here’s a brief excerpt:

Entrepreneurs don’t have to be in Silicon Valley to become the next great business success story. Toronto now ranks fourth among the world’s top 25 start-up ecosystems, according to Start-up Genome, a project that maps the success rates of start-ups. Toronto ranks just behind Silicon Valley, New York City and London.

OtoSim Inc. to Appear on BNN’s The Pitch

OtoSim Inc., a MaRS Innovation spin-off company, is taping an appearance on Business News Network’s The Pitch on May 22, 2012.

Louis Hui, OtoSim’s business development manager, will have 90 seconds to pitch OtoSim™ — an integrated educational system that dynamically and interactively teaches how to accurately diagnose ear diseases — to The Pitch’s panel of financiers and experts.

ScarX Therapeutics Featured on Front Page of the Globe and Mail

MaRS Innovation’s ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010.

Read the article on Globe and Mail.com (note that depending on when you’re accessing this page, the Globe‘s content may be subject to a pay wall).

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.

This project was covered in The Globe and Mail on May 7, 2012.

Two MI inventors named to MIT’s 35 inventors under 35 list

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

University of Toronto: Snapshot of Toronto’s Entrepreneurship Scene

OtoSim Inc. to Appear on BNN’s The Pitch

ScarX Therapeutics Featured on Front Page of the Globe and Mail

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

Quick Links

Contact Us